Predicting Factors for a Favorable Pathologic Response to Neoadjuvant Therapy in Esophageal Cancer

Ory Wiesel*, Oran Zlotnik, Sarah Morgenstern, Maya Tsur, Nikolai Menasherov, Yael Feferman, Irit Ben-Aharon, Hanoch Kashtan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background: Favorable pathologic response(FPR) is a significant predictor for improved survival following Neoadjuvant therapy(NAT) in esophageal and gastroesophageal cancer(GEJ). Preoperative prediction of FPR could modify treatment plans. No reliable method for predicting FPR exists. We sought to identify preoperative predicting factors for FPR. Materials and Methods: Retrospective analysis of patients with esophageal and GEJ cancer who underwent esophagectomy following (NAT). Univariate and multivariate analysis was used to identify preoperative predicting factors for FPR. A comparison of Tumor Regression Grade(TRG) was used to assess treatment response on overall survival(OS). Results: Out of 121 patients, 82(67.8%) had neoadjuvant chemoradiation. FPR was observed in 60(49.6%). Female sex, Radiation therapy(RT), squamous cell carcinoma(SCC), lack of signet ring feature, and FDG avidity posttreatment were associated with FPR on univariate analysis. RT and SCC were associated with FPR (OR=3.9 and 4.0, respectively) on multivariate analysis. OS was lower among patients who did not achieve FPR to NAT(P=0.027). Conclusions: FPR is a predictor of improved OS. SCC and radiation therapy-based protocol were identified as major prediction factors of FPR in patients with esophageal and GEJ cancers.

Original languageEnglish
Pages (from-to)514-518
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume45
Issue number12
DOIs
StatePublished - 1 Dec 2022

Keywords

  • esophageal cancer
  • esophagectomy
  • favorable pathologic response
  • gastroesophageal junction cancer
  • tumor regression grade

Fingerprint

Dive into the research topics of 'Predicting Factors for a Favorable Pathologic Response to Neoadjuvant Therapy in Esophageal Cancer'. Together they form a unique fingerprint.

Cite this